Effects of single or repeated amphetamine treatment and withdrawal on lung allergic inflammation in rats.
The effects of single or repeated amphetamine (AMPH) treatment and those of AMPH withdrawals on immune-mediated lung inflammatory response were studied in rats. Two experiments were done. In the first, rats egg-albumin (OVA) sensitized were singularly or repeatedly (21 days, once daily) treated with AMPH (1.0 mg/kg) or with a similar number and volume of 0.9% NaCl. The OVA aerosol challenge was performed 12 h after the single or last repeated AMPH treatment and also 72 and 120 h after AMPH withdrawal. In the second experiment, the effects of reserpine (1.0 mg/kg/day for 5 consecutive days) on single AMPH actions on lung allergic response of rats were analyzed. Single and repeated AMPH treatment induced opposite actions on Bronchoalveolar lavage fluid (BAL) cellularity of allergic rats: single treatment decreased and repeated treatment increased the total number of cells as well as those of macrophages, neutrophils and eosinophils. Our data also showed that single but not repeated AMPH treatment decreased the number of neutrophils, monocytes and lymphocytes in the peripheral blood, and increased the total number of bone marrow cells in rats sensitized and challenged with OVA. Furthermore, it was shown that reserpine treatment precluded the effects of single AMPH treatment on cellular migration to the lung of OVA-sensitized and challenged rats. It was concluded that AMPH effects on lung inflammatory response and cell recruitment to the lung in allergic rats rely at least partially on corticosterone serum levels. The possible involvement of vesicular monoamine transporter type 2 (VMAT2) with these observed effects was discussed.
Ligeiro de Oliveira
A P
AP
Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Lazzarini
R
R
Cavriani
G
G
Quinteiro-Filho
W M
WM
Tavares de Lima
W
W
Palermo-Neto
J
J
D000542:Alveolitis, Extrinsic Allergic / Q000473:pathology*; D000661:Amphetamine / Q000009:adverse effects* / Q000494:pharmacology*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D003345:Corticosterone / Q000097:blood; D007958:Leukocyte Count; D008168:Lung / Q000473:pathology*; D008297:Male; D010047:Ovalbumin / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D012110:Reserpine / Q000494:pharmacology; D013375:Substance Withdrawal Syndrome / Q000473:pathology*; D050493:Vesicular Monoamine Transport Proteins / Q000096:biosynthesis / Q000235:genetics
D014150:Antipsychotic Agents; C493454:Slc18a2 protein, rat; D050493:Vesicular Monoamine Transport Proteins; D012110:Reserpine; D010047:Ovalbumin; D000661:Amphetamine; D003345:Corticosterone